Rising Pharmaceuticals, a Rising Pharma Holdings Inc company, has launched and started commercial shipment of a generic version of Lyrica, (pregabalin) Capsules in the United States, it was reported yesterday.
The product is available in eight commercially available strengths, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, & 300mg.
Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. The product should only be taken as prescribed.
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis